Business development

BioAlliance Pharma has specific skills in Research & Development and notably in the areas of Pharmaceutical and Clinical development, as well as Registration. This has enabled our company to develop a first product, Loramyc®, now registered in 26 European countries, in the United States and in South Korea.

These achievements have proven our ability to successfully complete the development of innovative products and to sign commercial partnerships:

· In Europe: with Therabel (for Loramyc®)

· In the USA (for Oravig®, brand name of Loramyc® in the USA)

· And in Asia: with Handok and NovaMed in South Asia and with Sosei in Japan (for Loramyc®)

Based on this model, we are actively looking for strategic partnerships enabling a long-term growth based on our product franchises that address strong growing markets:

· Sitavir®, a product for the treatment of herpes labialis for retail markets or OTC. The pivotal Phase III positive final results obtained end of 2009 showed marked efficacy and good tolerance. These results have provided a good basis to define the registration strategy and the submission of Sitavir® (acyclovir Lauriad™) European registration dossier through a European decentralized procedure has been made in October 2011.

· A supportive care franchise for immunocompromised patients in the hospital setting consisting today of Loramyc® as well as two other products using the proprietary adhesive Lauriad™ technology:

- Fentanyl Lauriad™ in chronic cancer pain: positive preliminary results in the first Phase I clinical trial obtained in March 2010 showed the sustained systemic absorption of the product, meaning that administration for severe chronic cancer pain can be envisaged;

- Clonidine Lauriad™ in prevention and treatment of radiotherapy and chemotherapy-induced oral mucositis: ongoing Phase II clinical trial will evaluate efficacy and safety of clonidine Lauriad™ in patients with head and neck cancer.

· Innovative treatments for severe and invasive cancers and/or orphan drugs, including the biotherapy AMEP® for the treatment of metastatic melanoma, currently in a phase I clinical trial.

BioAlliance Pharma’s management team participates on a regular basis in the main international partnering conferences. Please use the form on the left in order to contact us.